Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel poliglumex + temozolomide
- Development stage
- Unknown
- Lead developer
- Sobi
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
Paclitaxel poliglumex (PPX) plus temozolomide is an investigational combination therapy studied primarily for the treatment of high-grade gliomas, including glioblastoma. Paclitaxel poliglumex is a macromolecular conjugate that links paclitaxel to poly-L-glutamic acid, designed to enhance tumor targeting and act as a potent radiation sensitizer. Temozolomide is an oral alkylating agent that induces DNA damage by methylating guanine residues, leading to cell death. The combination was evaluated with concurrent radiation therapy in clinical trials for newly diagnosed high-grade gliomas. However, the regimen was associated with significant grade 4 hematologic toxicity (notably myelosuppression), which limited its safety and further development as a combined regimen[1][2][5]. Despite this toxicity, some studies reported favorable progression-free and overall survival outcomes compared to standard therapies.
- Brand names
- OpaxioXyotaxTemodar
- Other names
- PPX + temozolomide
02
Targets
TUBB (Tubulin (alpha and beta subunits))O6-G (DNA guanine O6 position)
Beyond the preview
Go deeper on paclitaxel poliglumex + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel poliglumex + temozolomide.